Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological Variables Associated to Immune Checkpoint Inhibitor Toxicity in Cancer Patients
2023-505360-11-00Phase 2Authorised
- Sponsor
- Institut Jules Bordet
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in Nonhematologic neoplasms, Non-hematologic malignancy and cancer (3 cohorts), sponsored by Institut Jules Bordet. Planned start Jul 2023; status: authorised.
02
Drugs
03
Conditions
Nonhematologic neoplasmsNon-hematologic malignancycancer
Beyond the preview
Go deeper on 2023-505360-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505360-11-00.